Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Billions On The Line: Merck's HCV Patents Upheld In Gilead Lawsuit

This article was originally published in Scrip

Executive Summary

In a lawsuit that Gilead Sciences Inc. filed after receiving a request from Merck & Co. Inc. for royalties from Gilead's blockbuster hepatitis C drug Sovaldi (sofosbuvir), Merck may now be entitled to billions of dollars in royalties and damages after a jury validated the company's patents on March 22.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register